Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Olopatadine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

39 API Suppliers, 17 USDMF, 9 JDMF, 6 EU WC, 14 KDMF, 14 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

INTERMEDIATES

12 Intermediate Suppliers

12 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

85 FDF Dossiers, 35 FDA Orange Book, 13 Europe, 13 Canada, 2 South Africa, 22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION/DROPS;OPHTHALMIC - EQ 0.7% BASE, SOLUTION/DROPS;OPHTHALMIC - EQ 0.1% BASE, SOLUTION/DROPS;OPHTHALMIC - EQ 0.2% BASE, SPRAY, METERED;NASAL - 0.665MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 3 DKSH, 2 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 5 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 BASF, 1 Clariant, 10 Corel Pharma Chem, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 14 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 3 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives, 30 Fillers, Diluents & Binders, 19 Controlled & Modified Release, 14 Direct Compression, 12 Taste Masking, 12 Chewable & Orodispersible Aids, 11 Parenteral, 11 Solubilizers, 10 Granulation, 9 Disintegrants & Superdisintegrants, 7 Film Formers & Plasticizers, 7 Co-Processed Excipients, 6 Thickeners and Stabilizers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Rheology Modifiers, 3 Topical, 2 Coloring Agents, 1 Lubricants & Glidants, 1 Surfactant & Foaming Agents, 1 Emulsifying Agents

DIGITAL CONTENT

48 News #PharmaBuzz

48 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 12 Regulatory FDF Prices, 17 Annual Reports

MARKET PLACE

18 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

17 US Patents, 1 US Exclusivities, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 3 Others

ANALYTICAL

3 Analytical Methods

3 Analytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
30/12/2024	Seqens	France	PCAS FINLAND	51014-7733	OLOPATADINE HCL	2010-04-26	2025-12-31	BULK INGREDIENT	POWDER (1kg/kg)
30/12/2024	Medichem S.A	Spain	Medichem S.A.	53296-0078	Olopatadine HCl	2010-05-27	2025-12-31	BULK INGREDIENT	POWDER (75kg/75kg)

Olopatadine

Olopatadine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

39 API Suppliers

17 USDMF

9 JDMF

6 EU WC

14 KDMF

14 NDC API

24 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

11 Drugs in Development

INTERMEDIATES

12 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

85 FDF Dossiers

35 FDA Orange Book

13 Europe

13 Canada

2 South Africa

22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION/DROPS;OPHTHALMIC - EQ 0.7% BASE

SOLUTION/DROPS;OPHTHALMIC - EQ 0.1% BASE

SOLUTION/DROPS;OPHTHALMIC - EQ 0.2% BASE

SPRAY, METERED;NASAL - 0.665MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

3 DKSH

2 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

1 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

5 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

10 BASF

1 Clariant

10 Corel Pharma Chem

1 Finar

6 Gangwal Chemicals

4 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

14 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Novo Excipients

1 Pharmatrans-Sanaq

2 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

3 Roquette

6 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

2 The Dow Chemical Company

1 Ulanqab Kema New Material

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives

30 Fillers, Diluents & Binders

19 Controlled & Modified Release

14 Direct Compression

12 Taste Masking

12 Chewable & Orodispersible Aids

11 Parenteral

11 Solubilizers

10 Granulation

9 Disintegrants & Superdisintegrants

7 Film Formers & Plasticizers

7 Co-Processed Excipients

SPRAY, METERED;NASAL - 0.665MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons